"The successful on-time completion of cGMP manufacturing of the RC220 bisantrene formulation was a highlight of the quarter with a Certificate of Analysis (CoA) issued confirming the new formulation meets the specifications required for a human intravenous (IV) drug product."
TICK!!!
Ann: Quarterly Activity Report & Appendix 4C, page-2
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.47 |
Change
-0.080(5.16%) |
Mkt cap ! $247.5M | |||
| Open | High | Low | Value | Volume |
| $1.56 | $1.56 | $1.47 | $68.48K | 44.99K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2490 | $1.47 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.48 | 2941 | 1 |
View Market Depth
| Last trade - 13.52pm 20/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.47 |
Change
-0.080 ( 3.29 %) |
||||
| Open | High | Low | Volume | ||
| $1.57 | $1.57 | $1.47 | 4131 | ||
| Last updated 13.53pm 20/05/2024 ? | |||||
| RAC (ASX) Chart |